- Home
- KPLT vs UBX Comparison
KPLT vs UBX Comparison
Compare KPLT & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- UBX
- Stock Information
- Founded
- KPLT 2012
- UBX 2009
- Country
- KPLT United States
- UBX United States
- Employees
- KPLT N/A
- UBX N/A
- Industry
- KPLT Diversified Commercial Services
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- UBX Health Care
- Exchange
- KPLT Nasdaq
- UBX Nasdaq
- Market Cap
- KPLT 40.8M
- UBX 36.9M
- IPO Year
- KPLT N/A
- UBX 2018
- Fundamental
- Price
- KPLT $10.09
- UBX $1.94
- Analyst Decision
- KPLT Hold
- UBX Strong Buy
- Analyst Count
- KPLT 2
- UBX 2
- Target Price
- KPLT $12.00
- UBX $7.00
- AVG Volume (30 Days)
- KPLT 19.0K
- UBX 203.3K
- Earning Date
- KPLT 03-13-2025
- UBX 04-14-2025
- Dividend Yield
- KPLT N/A
- UBX N/A
- EPS Growth
- KPLT N/A
- UBX N/A
- EPS
- KPLT N/A
- UBX N/A
- Revenue
- KPLT $241,789,000.00
- UBX N/A
- Revenue This Year
- KPLT $12.92
- UBX N/A
- Revenue Next Year
- KPLT $6.23
- UBX $33.62
- P/E Ratio
- KPLT N/A
- UBX N/A
- Revenue Growth
- KPLT 14.99
- UBX N/A
- 52 Week Low
- KPLT $5.08
- UBX $0.94
- 52 Week High
- KPLT $23.54
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- KPLT 59.27
- UBX 48.69
- Support Level
- KPLT $9.00
- UBX $1.99
- Resistance Level
- KPLT $11.76
- UBX $2.17
- Average True Range (ATR)
- KPLT 0.68
- UBX 0.22
- MACD
- KPLT 0.04
- UBX -0.05
- Stochastic Oscillator
- KPLT 47.32
- UBX 22.41
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.